Diaprost AB

Diaprost AB was founded in 2005 based on the idea that the successful translation of PSA testing used to detect prostate cancer could serve as a personalized theranostic platform. The technology and patent applications were developed by key researchers from Lund University.Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radio physics, experimental medicine, and oncology. Our scientists are actively involved in some of the most renowned cancer research centers in the world. Diaprost's R&D efforts focus on prostate cancer, aiming to revolutionize personalized healthcare. The goal is to establish an antibody platform for in vivo diagnostics, simplifying and making the identification/detection of prostate cancer more reliable, as well as enabling targeted therapy.